CERTIORARI DENIED

sadly

20-1119 AMARIN PHARMA, INC., ET AL. V. HIKMA PHARMACEUTICALS, ET AL.

Live Thread on Twitter

https://twitter.com/danravicher/status/1301175752868737026

Low-Cost Drug Is First to Improve Covid Patients’ Survival

A low-cost anti-inflammatory drug is the first treatment shown to improve survival in patients with Covid-19, University of Oxford researchers said.....

V should work I would say

https://www.bloomberg.com/news/articles/2020-06-16/low-cost-drug-is-first-to-improve-covid-patients-survival?srnd=premium-europe

Wow weekly NRx jumping around 8,000
Will have to ask my friend to get an update on Monday and will keep u guys posted

Typo Mistake, my bad
January-2020 vs. January-2019 NORMALIZED Retail ONLY Data
Amazing Year-On-Year Increase Across the Board; 74% increase in TRx & 68% increase in NRx & 80% increase in Refills
It is worth mentioning that January 2019 vs January 2018 had the following increase; TRx +49% & NRx +70% & Refills +33%

V
TRx: 343,910 {vs 197,615; +74.03%} – 2nd ATH {ATH in Dec-2019 = 355,971}
NRx: 164,864 {vs 98,190; +67.90%} – ATH (164,864 instead of 168,864)
Ref: 179,045 {vs 99,426; +80.08%} – 2nd ATH {ATH in Dec-2019 = 196,381}


Jan-2019 vs Jan-2018
TRx: 197,615 {vs 132,638; +48.99%}
NRx: 98,190 {vs 57,751; +70.02%}
Ref: 99,426 {vs 74,887; +32.77%}

jeebray
the market is not stagnant at all
just fyi, jan-19 vs jan-18, sector trx increased 11%
jan-20 vs jan-19 sector trx increased close to 20%
and be sure this will more than increase in 2020 and beyond and it will all be driven by V only
If you consider this stagnant, well, nothing to say, I rest my case

JJPow
I wish
Asked a friend to email me the numbers and I updated my excel sheets.
Highly doubt I will be able to update numbers on a weekly basis, but hopefully once a month or once every 2 month

January-2020 vs. January-2019 NORMALIZED Retail ONLY Data
Amazing Year-On-Year Increase Across the Board; 74% increase in TRx & 68% increase in NRx & 80% increase in Refills
It is worth mentioning that January 2019 vs January 2018 had the following increase; TRx +49% & NRx +70% & Refills +33%

V
TRx: 343,910 {vs 197,615; +74.03%} – 2nd ATH {ATH in Dec-2019 = 355,971}
NRx: 168,864 {vs 98,190; +67.90%} – ATH
Ref: 179,045 {vs 99,426; +80.08%} –2nd ATH {ATH in Dec-2019 = 196,381}

Jan-2019 vs Jan-2018
TRx: 197,615 {vs 132,638; +48.99%}
NRx: 98,190 {vs 57,751; +70.02%}
Ref: 99,426 {vs 74,887; +32.77%}

Full Year-2019 vs. Full Year-2018 (NORMALIZED Retail ONLY Data)
After getting the monthly retail numbers for last Quarter, below you can find the numbers of Year 2019 vs Year 2018

V
TRx Year-2019 vs Year-2018 +77.81% – December TRx Numbers at ATH
NRx Year-2019 vs Year-2018 +84.48% – December NRx Numbers at ATH
Ref Year-2019 vs Year-2018 +72.22% – December Refills Numbers at ATH

Missed Scripts from 06-12-2019
Below the normalized numbers for V, L & GL + Market Share for weeks I didn't post.
I will be posting the monthly numbers later today and a comparison vs 2019 and 2018

NORMALIZED Scripts Update for Week Ending 14/02

ATH in NRx Numbers + ATH in TRx & NRx Market Share
2nd ATH in TRx & 3rd ATH in Refills Market Share

V
TRx: 83,880 {vs 81,935; +2.37%} Sector +1.86% --- (10,065,601 vs 9,832,206) -- 2nd ATH
NRx: 41,552 {vs 39,766; +4.49%} Sector +2.94% --- (4,986,256 vs 4,771,873) -- ATH
Ref: 42,328 {vs 42,169; +0.38%} Sector +0.81% --- (5,079,345 vs 5,060,333) -- 5th ATH

GenL
TRx: 59,416 {vs 58,810; +1.03%} (7,129,937 vs 7,057,241)
NRx: 29,704 {vs 29,440; +0.90%} (3,564,491 vs 3,532,779)

L
TRx: 853 {vs 776; +9.94%} (102,414 vs 93,155)
NRx: 337 {vs 342; -1.50%} (40,442 vs 41,058)

V TRx Market Share: 58.19% vs 57.90% --- ATH
V NRx Market Share: 58.04% vs 57.18% --- ATH
V Ref Market Share: 58.34% vs 58.59% --- 3rd ATH

13F ongoing release

Artisan Partners Limited Partnership just released their AMRN holding for Q4-2019 in which they increased their position by 2,911,233 shares and now have an AMRN position for a total of 16,055,421 shares

Tucaman

if you want, send me in private your Bloomberg username and password. I will log from Bloomberg Anywhere, retrieve the data and log out directly
This way I can update all my numbers, weekly, monthly, quarterly and post them here
Let me know if that's possible

Hello all fellow members,
Sorry I vanished the past few weeks, had to deal with few issues and now all is good.
To my surprise, I lost access to my terminal as we are switching away from Bloomberg, so sadly I am not able to update the weekly scripts for the foreseen future. Hopefully we can keep one terminal active and thus I can get the data from it.
Will keep you posted.
Great 2 in 1 news today, we're the only players in this huge worldwide market. Just need a smooth trial IP win or a settlement and this will fly high to the 30s easily

My Blood Test Results

Vascepa + Crestor 20mg working magic. Great positive results and change to the better from Frebruary-2019 until today. Nothing changed in my daily habits, quality and quantity of food and still not able to work out. Hopefully in the ocming year i will be able to do that.

Waiting for my Dr's reply, most probably will be reducing Crestor's dosage

My own personal Reduce-It :):)

Merry Christmas all and best wishes for the coming year.
Long & Strong AMARIN

October + November-2019 vs. October + November-2018 (NORMALIZED Retail ONLY Data)
Great start and increase for the beginning of Q4-2019 and along the way increasing the size of the market

V
TRx Oct/Nov-2019 vs Oct/Nov-2018 +81.70% – Sector +18.88%
NRx Oct/Nov-2019 vs Oct/Nov-2018 +77.05% – Sector +20.33%
Ref Oct/Nov-2019 vs Oct/Nov-2018 +85.90% – Sector +17.65%

Gen L
TRx Oct/Nov-2019 vs Oct/Nov-2018 -15.45%
NRx Oct/Nov-2019 vs Oct/Nov-2018 -12.31%
Refills Oct/Nov-2019 vs Oct/Nov-2018 -8.04%

L
TRx Oct/Nov-2019 vs Oct/Nov-2018 -39.14%
NRx Oct/Nov-2019 vs Oct/Nov-2018 -38.65%
Refills Oct/Nov-2019 vs Oct/Nov-2018 -39.47%

V Oct/Nov-2019 NORMALIZED Retail TRx Market Share: 54.52% vs 35.67% in Oct/Nov-2018
V Oct/Nov-2019 NORMALIZED Retail NRx Market Share: 54.25% vs 36.87% in Oct/Nov-2018
V Oct/Nov-2019 NORMALIZED Retail Ref Market Share: 54.76% vs 34.65% in Oct/Nov-2018

November-2019 vs. November-2018 NORMALIZED Retail ONLY Data
Amazing Year-On-Year Increase Across the Board; ~80% increase in TRx & ~72% increase in NRx & ~87% increase in Refills
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year ~+18% TRx & ~+19% NRx & ~+18% Refills) and at the same time increasing its own Market Share

V
TRx: 318,413 {vs 177,409; +79.48%} – Sector +18.15% -- 2nd ATH
NRx: 145,755 {vs 84,788; +71.91%} – Sector +18.44% -- 2nd ATH
Ref: 172,659 {vs 92,621; +86.41%} – Sector +17.90% -- 2nd ATH

Gen L
TRx: 254,786 {vs 304,446; -13.68%}
NRx: 117,883 {vs 136,561; -18.45%}

L
TRx: 3,934 {vs 6,629; -40.65%}
NRx: 1,580 {vs 2,575; -38.64%}

V November-2019 NORMALIZED Retail ONLY TRx Market Share: 55.17% vs 36.32% in November -2018 --- ATH
V November -2019 NORMALIZED Retail ONLY NRx Market Share: 54.96% vs 37.86% in November -2018 --- ATH
V November -2019 NORMALIZED Retail ONLY Ref Market Share: 55.35% vs 35.01% in November -2018 --- ATH

Total Monthly NORMALIZED Retail ONLY Data November-2019
Great Numbers – ATH Across the Board in Market Share & 2nd ATH Across the Board in Numbers

V
TRx: 318,413 {vs 326,711; -2.54%} – Sector -4.79% -- 2nd ATH (38,209,601 vs 39,205,289)
NRx: 145,755 {vs 152,705; -4.55%} – Sector -6.92% -- 2nd ATH(17,490,566 vs 18,324,581)
Ref: 172,659 {vs 174,006; -0.77%} – Sector -2.89% -- 2nd ATH(20,719,035 vs 20,880,708)

Gen L
TRx: 254,786 {vs 275,151; -7.40%} (30,574,364 vs 33,018,135)
NRx: 117,883 {vs 130,511; -9.68%} (14,145,969 vs 15,661,364)

L
TRx: 3,934 {vs 4,282; -8.12%} (472,125 vs 513,823)
NRx: 1,580 {vs 1,733; -8.82%} (189,649 vs 207,993)

Monthly NORMALIZED Retail TRx Market Share: 55.17% vs 53.90% --- ATH
Monthly NORMALIZED Retail NRx Market Share: 54.96% vs 53.59% --- ATH
Monthly NORMALIZED Retail Refills Market Share: 55.35% vs 54.17% --- ATH

For those interested in Old Scripts Numbers ATH Across the Board in Market Share & 2nd ATH in Numbers
V TRx 243,669 vs GL TRx 190,118 & L 2,591 -- 2nd ATH
V NRx 94,465 vs GL NRx 77,904 & L 878 -- 2nd ATH
V Refills 149,204 vs GL Refills 112,214 & L 1,713 -- 2nd ATH

SP Today
My personal opinion, lots were not expecting an approval before next week and they were loaded on options.
The past few days SP and today’s are all related to option expiry today and strike $21 is in play.
We will see if we close below or above it. Short and light trading sessions starting next week till after January 01 and from there proper pick up should kick start.
With regard to scripts, as you all know, numbers will trend lower till the reading seen 3rd week of January.
Long & Strong since 2012

NORMALIZED Scripts Update for Week Ending 13/12

ATH in NRx Numbers, 2nd ATH in TRx & Refills Numbers
ATH in Refills Market Share, 2nd ATH in TRx & 4th ATH in NRx Market Share

V
TRx: 82,684 {vs 83,269; -0.73%} Sector -0.96% --- (9,922,077 vs 9,995,466) -- 2nd ATH
NRx: 38,466 {vs 37,735; +1.94%} Sector +2.21% --- (4,615,931 vs 4,528,247) -- ATH
Ref: 44,218 {vs 45,560; -2.95%} Sector -3.62% --- (5,306,146 vs 5,467,219) -- 2nd ATH

GenL
TRx: 64,631 {vs 65,439; -1.23%} (7,755,711 vs 7,852,629)
NRx: 30,940 {vs 30,129; +2.69%} (3,712,759 vs 3,615,518)

L
TRx: 976 {vs 993; -1.76%} (117,076 vs 119,172)
NRx: 399 {vs 432; -7.70%} (47,834 vs 51,826)

V TRx Market Share: 55.76% vs 55.63% --- 2nd ATH Market Share
V NRx Market Share: 55.11% vs 55.25% --- 4th ATH Market Share
V Ref Market Share: 56.34% vs 55.95% --- ATH Market Share

For those interested in Old Scripts Numbers ATH in NRx Numbers, 2nd ATH in TRx & Refills Numbers. ATH in TRx & Redills Market Share – 3rd ATH in NRx Market Share;
V TRx 62,163 vs GL TRx 47,003 & L 616 -- ATH Market Share & 2nd ATH in Numbers
V NRx 24,449 vs GL NRx 19,910 & L 215 -- 3rd ATH Market Share & ATH in Numbers
V Refills 37,714 vs GL Refills 27,093 & L 401 -- ATH Market Share & 2nd ATH in Number

Trading after hours and after released approval news:
Thats 1million shares traded after the news and we are up $1.08 from $24.12 (last price before halt) to $25.20 (volume from 7.92million before halt and now it reached 8.92million)
Monday will be a super fun day
Congrats to all and 2020 is just the start :):)

INDICATIONS AND USAGE------------------------------
VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated:
• as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable
angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
o established cardiovascular disease or
o diabetes mellitus and 2 or more additional risk factors
for cardiovascular disease. (1)
• as an adjunct to diet to reduce TG levels in adult patients with severe
(≥ 500 mg/dL) hypertriglyceridemia. (1) Limitations of Use:
• The effect of VASCEPA on the risk for pancreatitis in patients with severe
hypertriglyceridemia has not been determined. (1)

Adam F u CI ing Feuerstein on Twitter
“Wanted 135. Also they didn’t get primary prevention


Yooo Adam, burn in hell with ur shorties friends. Lying about the fda press release, what a dumb f. U. C k

Amarin wins a block­buster ap­proval from the FDA. Now every­one can shift fo­cus to the patent

https://endpts.com/amarin-wins-a-blockbuster-approval-from-the-fda-now-everyone-can-shift-focus-to-the-patent-label/

Will Meade on Twitter

$AMRN Amarin was up almost 5% before the halt
$GILD Gilead was down almost 3% before the halt ??

I hope he’s wrong

7 years in the waiting....good luck to all, my gut feeling it’s the broadest label. Fingers crossed
JL, welcome back

NORMALIZED Scripts Update for Week Ending 06/12

ATH Across the Board in Numbers
2nd ATH in TRx & Refills Market Share, 3rd ATH in Refills Market Share

V
TRx: 83,269 {vs 67,887; +22.70%} Sector +24.12% --- (9,995,466 vs 8,146,400) -- ATH
NRx: 37,735 {vs 29,849; +26.42%} Sector +28.84% --- (4,528,247 vs 3,581,885) -- ATH
Ref: 45,560 {vs 38,038; +19.78%} Sector +20.43% --- (5,467,219 vs 4,564,515) -- ATH

GenL
TRx: 65,439 {vs 51,932; +26.01%} (7,852,629 vs 6,231,865)
NRx: 30,129 {vs 22,878; +31.70%} (3,615,518 vs 2,745,325)

L
TRx: 993 {vs 810; +22.61%} (119,172 vs 97,196)
NRx: 432 {vs 284; +52.22%} (51,826 vs 34,047)

V TRx Market Share: 55.63% vs 56.28% --- 2nd ATH Market Share
V NRx Market Share: 55.25% vs 56.31% --- 3rd ATH Market Share
V Ref Market Share: 55.95% vs 56.25% --- 2nd ATH Market Share

For those interested in Old Scripts Numbers ATH in TRx & Refills Numbers– 2nd ATH in NRx Numbers;
V TRx 63,459 vs GL TRx 48,673 & L 627 -- ATH
V NRx 24,267 vs GL NRx 19,868 & L 233 -- 2nd ATH
V Refills 39,192 vs GL Refills 28,805 & L 394 -- ATH

NORMALIZED Scripts Update for Week Ending 29/11
Super Short Thanksgiving Week
What’s important in short weeks is Market Share rather than Numbers
ATH Across the Board in Market Share

V
TRx: 67,887 {vs 79,042; -14.11%} Sector -15.53% --- (8,146,400 vs 9,485,011)
NRx: 29,849 {vs 37,510; -20.42%} Sector -21.51% --- (3,581,885 vs 4,501,166)
Ref: 38,038 {vs 41,532; -8.41%} Sector -10.16% --- (4,564,515 vs 4,983,845)

GenL
TRx: 51,932 {vs 62,792; -17.29%} (6,231,865 vs 7,534,988)
NRx: 22,878 {vs 29,653; -22.85%} (2,745,325 vs 3,558,403)

L
TRx: 810 {vs 968; -16.29%} (97,196 vs 116,107)
NRx: 284 {vs 375; -24.29%} (34,047 vs 44,970)

V TRx Market Share: 56.28% vs 55.35% --- ATH
V NRx Market Share: 56.31% vs 55.54% --- ATH
V Ref Market Share: 56.25% vs 55.18% --- ATH

For those interested in Old Scripts Numbers ATH in TRx & Refills Market Share – 2nd ATH in NRx Market Share;
V TRx 52,142 vs GL TRx 39,782 & L 518 -- ATH Market Share
V NRx 19,124 vs GL NRx 15,450 & L 156 -- 2nd ATH Market Share
V Refills 33,018 vs GL Refills 24,332 & L 362 -- ATH Market Share

JL

Can you please email me as i would like to discuss something with you
email: s81.sam81@gmail.com

Thanks

Roth Capital maintained Amarin Corporation (AMRN) coverage with Buy and target $31

Issuance Date: 2019-12-03

EH3A:GR Frankfurt
Amarin Corp PLC COMPANY INFO
20.20EUR +1.10 +5.76%
At current FX Rate that equates to ~ $22.25

NORMALIZED Scripts Update for Week Ending 22/11

1st full week after the ADCOM Vote
ATH Across the Board in Numbers & Market Share (except Refills Market Share 2nd ATH)
Great Weekly Increase in Scripts: +2,996 increase in TRx & +2,151 increase in NRx

V
TRx: 79,042 {vs 76,046; +3.94%} Sector +2.81% --- (9,485,011 vs 9,125,465) --- ATH
NRx: 37,510 {vs 35,359; +6.08%} Sector +4.25% --- (4,501,166 vs 4,243,085) --- ATH
Ref: 41,532 {vs 40,687; +2.08%} Sector +1.55% --- (4,983,845 vs 4,882,380) --- ATH

GenL
TRx: 62,792 {vs 61,870; +1.49%} (7,534,988 vs 7,424,450)
NRx: 29,653 {vs 29,041; +2.11%} (3,558,403 vs 3,484,898)

L
TRx: 968 {vs 986; -1.90%} (116,107 vs 118,354)
NRx: 375 {vs 385; -2.75%} (44,970 vs 46,240)

V TRx Market Share: 55.35% vs 54.75% --- ATH
V NRx Market Share: 55.54% vs 54.58% --- ATH
V Ref Market Share: 55.18% vs 54.90% --- 2nd ATH {ATH=55.21%}

For those interested in Old Scripts Numbers ATH Across the Board in Numbers & Market Share;
V TRx 60,097 vs GL TRx 46,233 & L 611 -- ATH
V NRx 24,308 vs GL NRx 19,386 & L 203 -- ATH
V Refills 35,789 vs GL Refills 26,847 & L 408 -- ATH

Raf, i will be posting them tomorrow
Happy Thanksgiving all

For Your Heart, Eat Fish Or Take Pills? A Dose Of This Drug Equals 8 Salmon Servings

https://www.npr.org/sections/health-shots/2019/11/25/781195172/for-heart-heart-eat-fish-or-take-pills-a-dose-of-this-drug-equals-8-salmon-servi

NORMALIZED Scripts Update for Week Ending 15/11

ATH in TRx & NRx Numbers & Market Share
2nd ATH in Refills Numbers & Market Share

V
TRx: 76,046 {vs 75,757; +0.38%} Sector -0.03% --- (9,125,465 vs 9,090,875) --- ATH
NRx: 35,359 {vs 34,382; +2.84%} Sector +1.22% --- (4,243,085 vs 4,125,792) --- ATH
Ref: 40,687 {vs 41,376; -1.67%} Sector -1.10% --- (4,882,380 vs 4,965,083) --- 2nd ATH

GenL
TRx: 61,870 {vs 62,303; -0.69%} (7,424,450 vs 7,476,231)
NRx: 29,041 {vs 29,238; -0.67%} (3,484,898 vs 3,508,524)

L
TRx: 986 {vs 890; +10.77%} (118,354 vs 106,848)
NRx: 385 {vs 386; -0.09%} (46,240 vs 46,282)

V TRx Market Share: 54.75% vs 54.52% --- ATH
V NRx Market Share: 54.58% vs 53.72% --- ATH
V Ref Market Share: 54.90% vs 55.21% --- 2nd ATH

For those interested in Old Scripts Numbers ATH Across the Board in Market Share & NRx Numbers. 2nd ATH in TRx & Refills Numbers ;
V TRx 57,738 vs GL TRx 45,271 & L 645 -- 2nd ATH
V NRx 22,864 vs GL NRx 18,810 & L 213 -- ATH
V Refills 34,874 vs GL Refills 26,461 & L 432 -- 2nd ATH

Both Invesco & Oppenheimer owe around 16 million share of AMRN as shown in filing as of 30/09/2019.
My question is, did they sell too early before ADCOM or played the option game and got exercised on selling covered calls after ADCOM and now looking to buy back in?

It is so hard to digest this analyst report that is not based on real science and market data and pumping a competitor with NO CV Trial in the horizon. Moreover the PT of $7 gives a fully diluted market cap of ~$2.9billion. Using a conservative price to sales multiple of just 3x, the report is assuming AMRN peak sale to be $970million, i.e just double what will AMRN achieve in 2019. That is a Horse BS big time

As per last release, they had 7.5 million shares
Did they sell too early and wants back in so using this piece of art what they call analyst??

Leland Gershell
Oppenheimer

He needs to be reported to SEC so they can track his trading on AMRN and also on Acasti
This is pure manipulation to pump Acasti since his firm handled their latest business and trying to benefit their clients.
Total BS I would say

Leland Gershell
Oppenheimer
Wall Street Analyst
Ranked #1,964 out of 5,681 Analysts on TipRanks (#3,709 out of 12,700 overall experts)
Leland Gershell's Performance
Success
Rate
45%
40 out of 88 ratings were successful

Average
Return
+3.5%
Average return per rating

His analysis is out of this world. And talking about a competitor that has NO CV trial.
This Gershell need to be reported to SEC so they check all his position before initiating such a report

BB

Done, please confirm receipt of email and PDF format